Zhe-Yu Hu
Overview
Explore the profile of Zhe-Yu Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu B, Hu Z, Xie N, Liu L, Li J, Yang X, et al.
Cancer Innov
. 2024 Oct;
3(6):e143.
PMID: 39464426
Background: CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor-positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate...
2.
Hu Z, Liu B, Xie N, Yang X, Liu L, Xiao H, et al.
BMC Cancer
. 2024 Jul;
24(1):915.
PMID: 39080554
Aims: This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. Methods: Data...
3.
Abula A, Ma S, Wang S, Peng W, Pei X, Hu Z
Front Immunol
. 2024 Jun;
15:1337400.
PMID: 38873609
Case Report: A 55-year-old male patient developed a mass in the left inguinal area with left lower limb swelling and first visited a local hospital 3 months earlier because of...
4.
Liu B, Xie N, Tian C, Feng R, Hu Z, Li J, et al.
Breast
. 2023 Nov;
72:103597.
PMID: 37944341
Background: Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast...
5.
Hu Z, Han F, Yu L, Jiang Y, Cai G
Innovation (Camb)
. 2023 Sep;
4(5):100494.
PMID: 37663933
No abstract available.
6.
Hu Z, Yan M, Xiong H, Ran L, Zhong J, Luo T, et al.
BMC Med
. 2023 Jun;
21(1):226.
PMID: 37365596
Background: Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic...
7.
Tang Y, Li J, Liu B, Ran J, Hu Z, Ouyang Q
Front Endocrinol (Lausanne)
. 2022 Dec;
13:1075830.
PMID: 36518248
Background: After early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. Genetic alterations may...
8.
Xie N, Zhou H, Yu L, Huang S, Tian C, Li K, et al.
Ann Transl Med
. 2022 Nov;
10(19):1067.
PMID: 36330383
Background: Ki-67 is a key indicator of the proliferation activity of tumors. However, no standardized criterion has been established for Ki-67 index calculation. Scale-invariant feature transform (SIFT) algorithm can identify...
9.
Tian C, Yang J, Xie N, Tang Y, Zhou H, Hu Z, et al.
Ann Transl Med
. 2022 Sep;
10(17):924.
PMID: 36172110
Background: Maintenance treatment following efficient chemotherapy can improve the treatment outcomes of patients with metastatic breast cancer (MBC). However, there are no studies for identifying the prognostic factors for patients...
10.
Hu Z, Tang Y, Liu L, Xie N, Tian C, Liu B, et al.
EClinicalMedicine
. 2022 Jul;
51:101567.
PMID: 35875816
Background: After multiple lines of therapies, no guideline or consensus is currently available for the treatment of patients with metastatic breast cancer. This study aims to evaluate the efficacy of...